Suven Life Sciences Limited (IN:SUVEN)
:SUVEN
Top Page
Suven Life Sciences Limited
(SUVEN)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹142.00
▼(-13.94% Downside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by very weak financial performance, including deteriorating profitability, negative gross profit in FY2025, and persistent operating/free-cash-flow burn despite low debt. Technicals are mixed with only short-term strength versus a longer-term downtrend, and valuation is constrained by a negative P/E and no stated dividend yield.
Positive Factors
Low leverage
Near-zero debt materially lowers solvency risk and preserves financial optionality over months. With minimal interest burden the company can prioritize restructuring, R&D or selective capital raises without heavy fixed financing costs, improving survival odds while earnings recover.
Negative Factors
Revenue decline
A material revenue drop signals waning demand or project loss, harming scale economics. Sustained declines reduce ability to cover fixed laboratory costs and erode bargaining power with clients, impairing prospects for margin recovery and investment in business-restoring initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Near-zero debt materially lowers solvency risk and preserves financial optionality over months. With minimal interest burden the company can prioritize restructuring, R&D or selective capital raises without heavy fixed financing costs, improving survival odds while earnings recover.
Read all positive factors
Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹34.21B
Dividend YieldN/A
Average Volume (3M)14.83K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees141
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-4.48
Shares Outstanding231,951,810
10 Day Avg. Volume16,308
30 Day Avg. Volume14,834
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)24.25
Price to Sales (P/S)400.69
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suven Life Sciences Limited Business Overview & Revenue Model
Company Description
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and...
How the Company Makes Money
Suven Life Sciences primarily makes money by providing contract research and development services to external customers, typically pharmaceutical and biotechnology companies. Revenue is generated through fee-based work for drug discovery and devel...
Suven Life Sciences Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.63M | 66.56M | 116.93M | 135.39M | 118.44M | 134.78M |
| Gross Profit | -151.32M | -276.33M | 108.69M | 129.74M | -137.31M | 133.75M |
| EBITDA | -2.06B | -1.55B | -992.78M | -1.11B | -1.17B | -721.87M |
| Net Income | -2.12B | -1.61B | -1.05B | -1.18B | -1.22B | -721.51M |
Balance Sheet | ||||||
| Total Assets | 3.37B | 1.35B | 2.85B | 3.89B | 1.08B | 1.28B |
| Cash, Cash Equivalents and Short-Term Investments | 2.59B | 600.05M | 2.40B | 2.31B | 504.36M | 463.54M |
| Total Debt | 0.00 | 0.00 | 7.10M | 16.05M | 32.09M | 47.64M |
| Total Liabilities | 561.36M | 251.97M | 148.62M | 135.91M | 118.89M | 204.12M |
| Stockholders Equity | 2.81B | 1.10B | 2.70B | 3.75B | 961.45M | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | -1.06B | -1.86B | -1.15B | -1.06B | -1.47B | -1.02B |
| Operating Cash Flow | -1.03B | -1.48B | -1.15B | -1.03B | -1.28B | -960.24M |
| Investing Cash Flow | -2.02B | 1.49B | 944.36M | -2.61B | -222.29M | 558.40M |
| Financing Cash Flow | 3.00B | -7.10M | -10.54M | 3.96B | 1.46B | 348.56M |
Suven Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹48.50B | 30.45 | ― | 0.13% | 14.35% | 15.79% | |
57 Neutral | ₹31.70B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
57 Neutral | ₹29.12B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ₹34.21B | -9.14 | ― | ― | ― | ― | |
41 Neutral | ₹39.06B | -13.56 | ― | ― | -0.82% | 34.67% |
* Healthcare Sector Average
IN:SUVEN
Suven Life Sciences Limited
147.50
16.25
12.38%
IN:AARTIDRUGS
Aarti Drugs Limited
347.30
0.41
0.12%
IN:GUFICBIO
Gufic Biosciences Limited
290.40
-52.36
-15.28%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
120.35
-29.60
-19.74%
IN:SUPRIYA
Supriya Lifescience Limited
602.65
-190.45
-24.01%
Suven Life Sciences Limited Corporate Events
Suven Life Sciences Opens Special Window for Re-Lodgment of Physical Share Transfers
Feb 19, 2026
Suven Life Sciences has notified stock exchanges that it has published newspaper advertisements announcing a special window for re-lodgment of transfer requests for physical securities. The notice, released in Business Standard and Nava Telangana ...
Suven Life Sciences Attributes Share Price Surge to Market Speculation
Feb 6, 2026
Suven Life Sciences Limited has responded to a query from the National Stock Exchange of India regarding a significant recent movement in its share price and trading volumes. The company stated that it has already been disclosing all material even...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.